Skip to content

Mindfulness Training for Smoking Cessation

Assessing Mindfulness Training as a Mechanistic Probe for Stress-Induced Brain Activation and Relapse Prevention for Tobacco Addiction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01144689
Enrollment
42
Registered
2010-06-15
Start date
2009-02-28
Completion date
2013-02-28
Last updated
2016-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking, Nicotine Dependence, Smoking Cessation, Tobacco Smoking

Keywords

mindfulness, smoking, stress

Brief summary

The purpose of this study is to assess the effects of mindfulness training (MT) compared to standard Smoking Cessation Therapy (SCT) on smoking cessation and stress provocation in individuals trying to quit smoking.

Interventions

BEHAVIORALMindfulness Training

8 sessions of behavioral treatment for smoking cessation

8 sessions of behavioral treatment for smoking cessation

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Between the ages of 18 and 60 2. Smoking 10 or more cigarettes per day 3. Fewer than 3 months of smoking abstinence in the past year 4. Motivated to stop smoking

Exclusion criteria

1. Current use of psychoactive medications that have not been at a stable dose for the past six months, are used as mood stabilizers, or are used as smoking cessation treatments. Individuals who are on psychoactive medications that are stable, not mood stabilizers, and not used for smoking cessations are excluded from fMRI sessions but not smoking cessation treatment. 2. Use of another investigational drug within 30 days 3. Any serious or unstable disease within 6 months 4. Meets criteria for substance dependence within the past year 5. Left handed (will be excluded from fMRI only)

Design outcomes

Primary

MeasureTime frame
Between group differences in continuous abstinenceduring treatment and 6, 12 and 18 weeks after treatment initiation

Secondary

MeasureTime frame
Between group differences in perceived stress6, 12 and 18 weeks after treatment initiation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026